Telephus is developing TPH 101, a first-in-class humanized monoclonal antibody to prevent Staphylococcus reinfection and accompanying osteomyelitis in patients receiving total hip arthroplasty (THA) or total knee arthroplasty (TKA) septic revision surgery.  Focused on preventing the early events that lead to biofilm deposition on implantable devices, we are dedicated to improving outcomes for joint replacement procedures – a necessity where there is a growing unmet medical need for reducing complications from arthroplasty procedures in a population where people are living longer, more active lives.

Telephus was founded in 2012 and is based in San Diego, California.